• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2002 年版肿瘤-淋巴结-转移分期在局部进展期肝细胞癌中的应用:能否预测手术结局?

Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

机构信息

State Key Laboratory of Oncology in South China, Guangzhou, China.

出版信息

BMC Cancer. 2010 Oct 7;10:535. doi: 10.1186/1471-2407-10-535.

DOI:10.1186/1471-2407-10-535
PMID:20925965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2958946/
Abstract

BACKGROUND

Locally advanced (pT3-4N0M0) hepatocellular carcinoma (HCC) is a heterogeneous group of tumors, which consists of four different categories, including HCC with "multiple tumors more than 5 cm", "major vascular invasion", "invasion of adjacent organs", and "perforation of visceral peritoneum". The aim of our study was to verify whether the 2002 version of the Tumor-Node-Metastasis staging system could predict surgical outcomes in patients with locally advanced HCC.

METHODS

We retrospectively reviewed 298 patients with pT3-4N0M0 HCC who underwent hepatic resection from 1993 to 2000 in an academic tertiary hospital. Overall survival (OS) and cumulative recurrence rate (CRR) of the four categories of locally advanced HCC patients were compared.

RESULTS

In multivariate analysis, major vascular invasion was identified as the most significant factor (HR = 3.291, 95% CI 2.362-4.584, P < 0.001) followed by cirrhosis status on OS, and was found to be the only independent factor of CRR (HR = 2.242, 95% CI 1.811-3.358, P < 0.001) in patients with locally advanced HCC. Among the four categories of locally advanced HCC, OS was significantly worse, and CRR was significantly higher in patients with HCC with major vascular invasion (pT3) than with multiple tumors more than 5 cm (pT3); or tumor invasion of adjacent organs (pT4); or perforation of visceral peritoneum (pT4). No significant differences were observed in OS or CRR between the latter three groups of patients.

CONCLUSIONS

HCC with major vascular invasion, which are classified as pT3 under the current TNM staging, have the worst prognosis when compared with the other categories of pT3-4 disease. There is a need to redefine the T classification and to stratify locally advanced HCC.

摘要

背景

局部进展期(pT3-4N0M0)肝细胞癌(HCC)是一组异质性肿瘤,包括四种不同类型,包括“多个肿瘤大于 5cm”、“主要血管侵犯”、“邻近器官侵犯”和“内脏腹膜穿孔”的 HCC。我们的研究旨在验证 2002 年版肿瘤-淋巴结-转移分期系统是否能预测局部进展期 HCC 患者的手术结局。

方法

我们回顾性分析了 1993 年至 2000 年在一家学术性三级医院接受肝切除术的 298 例 pT3-4N0M0 HCC 患者。比较了四种局部进展期 HCC 患者的总生存率(OS)和累积复发率(CRR)。

结果

多因素分析显示,主要血管侵犯是最重要的因素(HR=3.291,95%CI2.362-4.584,P<0.001),其次是 OS 时的肝硬化状态,是局部进展期 HCC 患者 CRR 的唯一独立因素(HR=2.242,95%CI1.811-3.358,P<0.001)。在四种局部进展期 HCC 中,伴有大血管侵犯(pT3)的 HCC 患者的 OS 显著较差,CRR 显著较高(pT3)比多个肿瘤大于 5cm(pT3);或肿瘤侵犯邻近器官(pT4);或内脏腹膜穿孔(pT4)。后三组患者的 OS 或 CRR 无显著差异。

结论

目前 TNM 分期中归类为 pT3 的伴有大血管侵犯的 HCC 与其他 pT3-4 疾病相比预后最差。有必要重新定义 T 分期并对局部进展期 HCC 进行分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec75/2958946/34e83c908b83/1471-2407-10-535-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec75/2958946/0bdadfeb93f5/1471-2407-10-535-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec75/2958946/34e83c908b83/1471-2407-10-535-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec75/2958946/0bdadfeb93f5/1471-2407-10-535-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec75/2958946/34e83c908b83/1471-2407-10-535-2.jpg

相似文献

1
Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?2002 年版肿瘤-淋巴结-转移分期在局部进展期肝细胞癌中的应用:能否预测手术结局?
BMC Cancer. 2010 Oct 7;10:535. doi: 10.1186/1471-2407-10-535.
2
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification.IV期A组肝细胞癌肝切除术后的预后:重新分类的必要性。
Ann Surg. 2003 Mar;237(3):376-83. doi: 10.1097/01.SLA.0000055224.68432.80.
3
[A new prognostic score system of hepatocellular carcinoma following hepatectomy].[一种肝切除术后肝细胞癌的新预后评分系统]
Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):903-909. doi: 10.3760/cma.j.issn.0253-3766.2017.12.005.
4
A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy.改良的 TNM-7 分期系统可更好地预测肝癌患者肝切除术后的生存情况。
J Cancer Res Clin Oncol. 2013 Oct;139(10):1709-19. doi: 10.1007/s00432-013-1497-y. Epub 2013 Aug 28.
5
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.伴有门静脉癌栓的晚期肝细胞癌肝切除术后的生存率
World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246.
6
The Impact of Serosal Invasion on Prognosis after Curative Hepatectomy for Hepatocellular Carcinoma: Invasion to Adjacent Organs and Rupture of Tumor Were Crucial Tumor-Related Prognostic Factors Needed for Survival.肝细胞癌根治性肝切除术后浆膜侵犯对预后的影响:侵犯邻近器官和肿瘤破裂是生存所需的关键肿瘤相关预后因素。
Dig Surg. 2018;35(2):155-163. doi: 10.1159/000477270. Epub 2017 Aug 9.
7
Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation.局部区域治疗对肝癌肝移植前降期的疗效。
Hepatobiliary Pancreat Dis Int. 2011 Apr;10(2):143-50. doi: 10.1016/s1499-3872(11)60023-4.
8
Predictors and patterns of recurrence after resection of hepatocellular carcinoma.肝细胞癌切除术后复发的预测因素及模式
J Am Coll Surg. 2003 Nov;197(5):753-8. doi: 10.1016/j.jamcollsurg.2003.07.003.
9
[Correlation of carcinoembryonic antigen with prognosis of hepatocellular carcinoma after hepatectomy].[癌胚抗原与肝癌肝切除术后预后的相关性]
Zhonghua Zhong Liu Za Zhi. 2014 Jun;36(6):430-4.
10
Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?肝癌患者的病理TNM分期系统能否预测预后?
Cancer. 2000 Feb 1;88(3):538-43. doi: 10.1002/(sici)1097-0142(20000201)88:3<538::aid-cncr7>3.0.co;2-h.

引用本文的文献

1
Prognostic comparison between LNM and MaVI of hepatocellular carcinoma: a multicenter population-based propensity scores matching study.肝细胞癌淋巴结转移与微血管侵犯的预后比较:一项基于多中心人群的倾向评分匹配研究
BMC Gastroenterol. 2025 Aug 26;25(1):618. doi: 10.1186/s12876-025-03639-y.
2
Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy.肿瘤大小可能会影响无大血管侵犯肝硬化单发肝细胞癌患者术后的预后。
Sci Rep. 2021 Aug 11;11(1):16343. doi: 10.1038/s41598-021-95835-5.
3
Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study.

本文引用的文献

1
Surgical treatment of hepatocellular carcinoma.肝细胞癌的外科治疗。
Surg Today. 2009;39(10):833-43. doi: 10.1007/s00595-008-4024-z. Epub 2009 Sep 27.
2
Molecular targeted therapies in hepatocellular carcinoma.肝细胞癌的分子靶向治疗
Hepatology. 2008 Oct;48(4):1312-27. doi: 10.1002/hep.22506.
3
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
巴塞罗那临床肝癌A期多灶性肝细胞癌的手术切除与消融治疗:一项倾向评分匹配研究
J Cancer. 2019 Jun 2;10(13):2857-2867. doi: 10.7150/jca.31246. eCollection 2019.
4
The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis.临床显著门静脉高压在肝细胞癌患者肝切除术中的作用:一项倾向评分匹配分析
BMC Cancer. 2015 Apr 11;15:263. doi: 10.1186/s12885-015-1280-3.
5
Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion.肿瘤大小不独立影响无肉眼血管侵犯的单发肝细胞癌根治性切除术后的长期生存。
World J Surg. 2014 Apr;38(4):947-57. doi: 10.1007/s00268-013-2365-2.
6
A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy.改良的 TNM-7 分期系统可更好地预测肝癌患者肝切除术后的生存情况。
J Cancer Res Clin Oncol. 2013 Oct;139(10):1709-19. doi: 10.1007/s00432-013-1497-y. Epub 2013 Aug 28.
7
Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system.评估接受根治性切除术的肝细胞癌患者的第七版美国癌症联合委员会肿瘤-淋巴结-转移(TNM)分期系统:对制定改良分期系统的启示。
HPB (Oxford). 2013 Jun;15(6):439-48. doi: 10.1111/j.1477-2574.2012.00617.x. Epub 2012 Dec 2.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
4
Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma.复发性和原发性肝细胞癌多中心起源及肝内转移的克隆性分析
J Gastrointest Surg. 2008 Sep;12(9):1540-7. doi: 10.1007/s11605-008-0591-y. Epub 2008 Jul 16.
5
Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery?IV A期肝细胞癌的治疗:我们是否应该重新评估手术的作用?
Arch Surg. 2008 Jun;143(6):538-43; discussion 543. doi: 10.1001/archsurg.143.6.538.
6
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.多发性肿瘤和门静脉高压均不是肝细胞癌的手术禁忌证。
Gastroenterology. 2008 Jun;134(7):1908-16. doi: 10.1053/j.gastro.2008.02.091. Epub 2008 Mar 8.
7
AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement.AHPBA/AJCC肝细胞癌分期共识会议:共识声明
HPB (Oxford). 2003;5(4):243-50. doi: 10.1080/13651820310015833.
8
Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study.肝细胞癌肝切除术后肝内复发患者的预后:一项回顾性研究。
Eur J Surg Oncol. 2009 Feb;35(2):174-9. doi: 10.1016/j.ejso.2008.01.027. Epub 2008 Mar 5.
9
Novel advancements in the management of hepatocellular carcinoma in 2008.2008年肝细胞癌管理方面的新进展。
J Hepatol. 2008;48 Suppl 1:S20-37. doi: 10.1016/j.jhep.2008.01.022. Epub 2008 Feb 12.
10
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.